Gauckler, P;
Shin, JI;
Alberici, F;
Audard, V;
Bruchfeld, A;
Busch, M;
Cheung, CK;
... RITERM study group, .; + view all
(2020)
Rituximab in adult minimal change disease and focal segmental glomerulosclerosis - What is known and what is still unknown?
Autoimmunity Reviews
, Article 102671. 10.1016/j.autrev.2020.102671.
(In press).
Preview |
Text
1-s2.0-S1568997220302469-main.pdf - Published Version Download (4MB) | Preview |
Abstract
Primary forms of minimal change disease and focal segmental glomerulosclerosis are rare podocytopathies and clinically characterized by nephrotic syndrome. Glucocorticoids are the cornerstone of the initial immunosuppressive treatment in these two entities. Especially among adults with minimal change disease or focal segmental glomerulosclerosis, relapses, steroid dependence or resistance are common and necessitate re-initiation of steroids and other immunosuppressants. Effective steroid-sparing therapies and introduction of less toxic immunosuppressive agents are urgently needed to reduce undesirable side effects, in particular for patients whose disease course is complex. Rituximab, a B cell depleting monoclonal antibody, is increasingly used off-label in these circumstances, despite a low level of evidence for adult patients. Hence, critical questions concerning drug-safety, long-term efficacy and the optimal regimen for rituximab-treatment remain unanswered. Evidence in the form of large, multicenter studies and randomized controlled trials are urgently needed to overcome these limitations.
| Type: | Article |
|---|---|
| Title: | Rituximab in adult minimal change disease and focal segmental glomerulosclerosis - What is known and what is still unknown? |
| Location: | Netherlands |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1016/j.autrev.2020.102671 |
| Publisher version: | https://doi.org/10.1016/j.autrev.2020.102671 |
| Language: | English |
| Additional information: | This is an open access article under the CC BY license (http://creativecommons.org/licenses/BY/4.0/). |
| Keywords: | Nephrotic syndrome, Rituximab, Minimal change disease, Focal segmental glomerulosclerosis, Long-term remission, Infections |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine > Renal Medicine |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10111038 |
Archive Staff Only
 |
View Item |
